Clinical Trials Logo

Essential Hypertension clinical trials

View clinical trials related to Essential Hypertension.

Filter by:

NCT ID: NCT03649646 Recruiting - Clinical trials for Essential Hypertension

FimasaRtan-basEd BP Targets After Drug SwitcHing

Start date: July 3, 2018
Study type: Observational

Among major risk factors for stroke and major cardiovascular diseases, hypertension needs to be managed proactively as it can be controlled with the aid of proper drugs. There are still many occasions with unsatisfactory result of hypertension control even though a wide class of antihypertensive drugs are available. This is because factors affecting the effects of selected antihypertensive drugs such as the underlying disease, other concomitant medications, and treatment compliance of each patient are different. Especially, the timing for treatment initiation should vary depending on the risk of cardio-cerebrovascular disease, and studies on target blood pressure (BP) criteria require study results in actual treatment setting with a broad range of patients. The recent hypertension clinical practice guidelines published by American College of Cardiology (ACC) and American Heart Association (AHA) reduced the target BP to 130/80 mmHg, indicating the needs for more aggressive efforts in hypertension treatment. However, studies in Koreans must be preceded before applying such new overseas guidelines; thus, this study has been designed to establish clinical materials reflecting treatment setting in Korea. In this study, patients with uncontrolled hypertension whose antihypertensive regimens are changed to ARB-based therapy (ARB monotherapy or ARB-containing combination therapy) will be followed to assess the treatment trend, treatment effect, and risk of cardiovascular disease.

NCT ID: NCT03566654 Not yet recruiting - Clinical trials for Essential Hypertension

Clinical Trial on Remote Ischemic Conditioning and Hypertension(HOPE)

Start date: July 2018
Phase: Phase 2
Study type: Interventional

Nowadays, the incidence of stroke in China has reached 1.6‰, and this disease has became a primary cause of death in China. One of its major risk factors is hypertension. As shown in the researches, the risk of stroke grows remarkably when the blood pressure increases and there exists a log-linear relationship between them. Systolic pressure and diastolic pressure relate to the risk of stroke independently. Systolic pressure decreasing 10mmHg will reduce the stroke risk by 31% and decrease of 1~3mmHg will reduce the stroke risk by 20~30%. As to diastolic pressure, 5mmHg decrease of it will reduce the stroke risk by 34% and 10mmHg decrease of it will reduce the stroke risk by 56%. In addition, patients with isolated systolic hypertension (SPB≥160mmHg, DPB≤90mmHg) or critical isolated systolic hypertension (SPB=140~159mmHg, DPB< 90mmHg) will suffer a higher risk of stroke than people with normal blood pressure. The ACC has already revised its Hypertension Management Guidelines of standard of diagnosis for hypertension and timing of starting medical treatment in hypertensive patients.Because more and more reseaches shown that people with blood pressure between 120-139/80-89mmHg have higher risk of ASCVSD compared to those with blood pressure lower than 120/80mmHg; However, in China, the diagnostic criteria for hypertension has not been revised yet. Therefore, we still have blind spot in treating such patients who suffer from borderline systolic hypertension at 130~140 mmHg of blood pressure with or without ASCVD or those with the first stage hypertension but refusing to take anti-hypertension drugs. What is more, most of them are middle-aged adults, once they have stroke, it would lead terrible and costly consequences to both their family and the society. Thus, it is necessary to explore new non-pharmacological methods to control blood pressure for reducing the risk of stroke.

NCT ID: NCT03514641 Active, not recruiting - Clinical trials for Essential Hypertension

An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension

Start date: October 18, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

This integrated assessment consists of two studies, 603A and 603B, to be carried out sequentially in a common study population. Participating subjects will be informed of the trial design and their consent to participate in both studies will be obtained in a single consent form. Approximately 680 male or female adult subjects will be enrolled.

NCT ID: NCT03371797 Recruiting - Clinical trials for Essential Hypertension

Amlodipine VaLsartan Efficacy in Hypertensive Patients.A Real World Trial

Start date: February 20, 2018
Study type: Observational

To determine the efficacy of valsartan/amlodipine 80/5 mg once daily dose is reducing mean sitting systolic blood pressure (MSSBP) and mean sitting diastolic blood pressure (MSDBP) after 8 weeks of therapy.

NCT ID: NCT03226340 Recruiting - Clinical trials for Essential Hypertension

S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension

Start date: December 2, 2015
Phase: Phase 4
Study type: Interventional

Evaluation of the Efficacy and Safety of S-amlodipine+Chlorthalidone Combination Therapy and S-amlodipine+Telmisartan Combination Therapy in Hypertensive Patients Inadequately Controlled With CCB(Calcium Channel Blocker) Monotherapy

NCT ID: NCT03156842 Recruiting - Dyslipidemia Clinical Trials

Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia

Start date: May 29, 2017
Phase: Phase 3
Study type: Interventional

The objective of this clinical study is to evaluate the efficacy and safety by comparing the fimasartan/amlodipine/rosuvastatin treatment group to the fimasartan/amlodipine treatment group and the fimasartan/rosuvastatin treatment group respectively at Week 8 in patients with essential hypertension and dyslipidemia who fail to respond to the fimasartan monotherapy.

NCT ID: NCT03063697 Enrolling by invitation - Clinical trials for Congestive Heart Failure

Observational Study to Evaluate the Safety of DILATREND SR Cap. in Korean Patients With Essential Hypertension, Chronic Stable Angina and Congestive Heart Failure

Start date: November 2015
Phase: N/A
Study type: Observational

The purpose of this study is to Evaluate the Safety of DILATREND SR Cap. in Korean Patients with Essential hypertension, Chronic stable angina and Congestive heart failure for 52 weeks.

NCT ID: NCT02944734 Completed - Clinical trials for Essential Hypertension

Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension

Start date: September 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the optimal dose of fixed-dose combination of candesartan cilexetil and amlodipine besylate by examining the safety and efficacy of the combination therapy compared to each of the monotherapy in patients with essential hypertension.

NCT ID: NCT02938910 Completed - Healthy Clinical Trials

Study of Myocardial Interstitial Fibrosis in Hyperaldosteronism

Start date: November 2012
Phase: N/A
Study type: Observational

Animal models have demonstrated the role of aldosterone in left ventricular remodeling involving fibrosis, apoptosis and hypertrophy. Myocardial fibrosis is a risk factor for serious arrhythmia and sudden death in ischemic and idiopathic hypertrophic heart disease. It is accepted that patients with primary aldosteronism have a higher prevalence of LV hypertrophy , arterial involvement and increased cardiovascular risk. In humans, a link has been demonstrated between aldosterone and heart failure as well as the benefit of the administration of an anti -aldosterone drug to lower mortality in this population , regardless of blood pressure level . The administration of spironolactone ( aldosterone ) in hypertensive rats has prevented the occurrence of aortic fibrosis . Plasma aldosteronism in humans has been associated with inflammation, fibrosis and aortic stiffness . However, primary aldosteronism is generally associated with so-called secondary hypertension . Chronic hypertension alone is a recognized etiological factor of myocardial hypertrophy ( myocardial fibrosis very advanced ) . The purpose of this study is to investigate the effects of MRI hyperaldosteronism on the heart.

NCT ID: NCT02890173 Completed - Clinical trials for Essential Hypertension

Study of CS-3150 in Patients With Essential Hypertension

Start date: September 2016
Phase: Phase 3
Study type: Interventional

To evaluate antihypertensive effect and safety of CS-3150 compared to Eplerenone in patients with essential hypertension.